Robinson Matthew K, Shaller Calvin, Garmestani Kayhan, Plascjak Paul S, Hodge Kathryn M, Yuan Qing-An, Marks James D, Waldmann Thomas A, Brechbiel Martin W, Adams Gregory P
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Clin Cancer Res. 2008 Feb 1;14(3):875-82. doi: 10.1158/1078-0432.CCR-07-1250.
Successful radioimmunotherapy strategies depend on selecting radioisotopes with physical properties complementary to the biological properties of the targeting vehicle. Small, engineered antitumor antibody fragments are capable of rapid, highly specific tumor targeting in immunodeficient mouse models. We hypothesized that the C6.5 diabody, a noncovalent anti-HER2 single-chain Fv dimer, would be an ideal radioisotope carrier for the radioimmunotherapy of established tumors using the short-lived alpha-emitting radioisotope (211)At.
Immunodeficient nude mice bearing established HER2/neu-positive MDA-MB-361/DYT2 tumors treated with N-succinimidyl N-(4-[(211)At]astatophenethyl)succinamate ((211)At-SAPS)-C6.5 diabody. Additional cohorts of mice were treated with (211)At-SAPS T84.66 diabody targeting the carcinoembryonic antigen or (211)At-SAPS on a diabody specific for the Müllerian inhibiting substance type II receptor, which is minimally expressed on this tumor cell line.
A single i.v. injection of (211)At-SAPS C6.5 diabody led to a 30-day delay in tumor growth when a 20 muCi dose was administered and a 57-day delay in tumor growth (60% tumor-free after 1 year) when a 45 muCi dose was used. Treatment of mice bearing the same tumors with (211)At-SAPS T84.66 diabody at the same doses led to a delay in tumor growth, but no complete responses, likely due to substantially lower expression of this antigen on the MDA-MB-361/DYT2 tumors. In contrast, a dose of 20 muCi of (211)At-SAPS on the anti-Müllerian-inhibiting substance type II receptor diabody did not affect tumor growth rate, demonstrating specificity of the therapeutic effect.
These findings indicate that diabody molecules can be effective agents for targeted radioimmunotherapy of solid tumors using powerful, short-lived alpha-emitting radioisotopes.
成功的放射免疫治疗策略依赖于选择物理性质与靶向载体生物学性质互补的放射性同位素。小型的、经过工程改造的抗肿瘤抗体片段能够在免疫缺陷小鼠模型中快速、高度特异性地靶向肿瘤。我们推测,C6.5双抗体(一种非共价抗HER2单链Fv二聚体)将是使用短寿命发射α粒子的放射性同位素砹-211(²¹¹At)对已形成肿瘤进行放射免疫治疗的理想放射性同位素载体。
用N-琥珀酰亚胺基N-(4-[(²¹¹At]砹苯乙基)琥珀酸酯(²¹¹At-SAPS)-C6.5双抗体治疗携带已形成的HER2/neu阳性MDA-MB-361/DYT2肿瘤的免疫缺陷裸鼠。另外几组小鼠用靶向癌胚抗原的²¹¹At-SAPS T84.66双抗体或用对苗勒管抑制物质II型受体具有特异性的双抗体上的²¹¹At-SAPS进行治疗,该受体在这种肿瘤细胞系上表达极少。
静脉内单次注射²¹¹At-SAPS C6.5双抗体,当给予20微居里剂量时,肿瘤生长延迟30天;当使用45微居里剂量时,肿瘤生长延迟57天(1年后60%无瘤)。用相同剂量的²¹¹At-SAPS T84.66双抗体治疗携带相同肿瘤的小鼠,导致肿瘤生长延迟,但无完全缓解,这可能是由于该抗原在MDA-MB-361/DYT2肿瘤上的表达显著较低。相比之下,20微居里剂量的抗苗勒管抑制物质II型受体双抗体上的²¹¹At-SAPS对肿瘤生长速率无影响,证明了治疗效果的特异性。
这些发现表明,双抗体分子可以成为使用强大的、短寿命发射α粒子的放射性同位素对实体瘤进行靶向放射免疫治疗的有效药物。